Health Condition 1: N859- Noninflammatory disorder of uterus, unspecified
Conditions
Interventions
Intervention1: Superior hypogastric plexus block: Superior hypogastric plexus block with dexmedetomidine which is expected to provide pain relief for twelve hours
Control Intervention1: Sham group: S
Sponsors
MIOT Hospitals
Eligibility
Inclusion criteria
Inclusion criteria: Patient with MRI confirmed symptomatic fibroid/s willing to undergo minimally invasive image guided procedure.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Infection in groin, lower abdomen and pelvis. 2. Concomitant pelvic or skin or spine diseases that cause pain in the pelvis. 3. Patient with known psychiatric diseases on medications like depression and anxiety. 4. Patients with adenomyosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the mean morphine dose equivalents (MME) in postoperative period in patients undergoing UAE with SHNB (ropivacaine, dexmedetomidine) and Sham procedure. Group A: Patients undergoing SHNB with ropivacaine Group B: Patients undergoing sham procedure (skin wheal at infraumbilical region). Timepoint: To compare the mean morphine dose equivalents (MME) in postoperative period in patients undergoing UAE with SHNB (ropivacaine, dexmedetomidine) and Sham procedure. Group A: Patients undergoing SHNB with ropivacaine Group B: Patients undergoing sham procedure (skin wheal at infraumbilical region). Time points will be assessed as during procedure, 12 hours after procedure, 12 hours to discharge after procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare procedure related complications in both groupsTimepoint: To compare procedure related complications in both groups. For both groups in first twelve hours after the procedure | — |
Countries
India
Contacts
Public ContactLogesvar Salarapatty Palanisamy
MIOT Hospitals
Outcome results
None listed